SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirms strong quarterly results and upbeat outlook drew bullish attention and analyst upgrades, but shares gave back much of their initial post-earnings rally. Traders debate whether the pullback reflects profit-taking or broader concerns about interest rates, consumer credit and the BNPL outlook.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons quarterly earnings beat, powered by unusually strong refining and fuel margins that outweighed weaker upstream results, is the dominant catalyst behind attention. Traders welcomed the results and shareholder returns, while some questioned whether refining profits can last and viewed the stocks run-up as stretched.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

OXY is drawing attention as shares break toward recent highs alongside strength in oil stocks, with traders highlighting call-heavy options activity and bullish technical signals. Some remain cautious about resistance and the stocks uneven response to crude-price moves.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,559,996,383.70523. The last known price of Dogecoin is 0.07552377 USD and is down -0.48 over the last 24 hours. It is currently trading on 1543 active market(s) with $337,365,256.17 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

DOGEs weak, range-bound trading around the 8-cent area dominates discussion, with traders pointing to repeated failures to reclaim that level and bearish or consolidation chart setups. Dip-buyers and long-term holders remain hopeful, while frustrated traders cite further downside and lingering losses; no specific confirmed catalyst stands out.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 11.67852871 USD and is up 2.18 over the last 24 hours. It is currently trading on 2313 active market(s) with $325,834,414.23 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

LINKs sharp rebound and repeated tests of resistance are driving attention, alongside optimism about Chainlinks institutional and tokenization integrations, including CCIP updates. Bulls view adoption and recent momentum as reasons to accumulate, while skeptics point to weak follow-through, sell pressure, and uncertainty over how network usage benefits the token.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA submission for sonelokimab in hidradenitis suppurativa and the pending FDA decision on whether to accept it for review are the main focus. Traders are split between seeing the regulatory milestone as a potential catalyst and worrying about approval risk, a solo commercial launch, and possible dilution; the stocks decline has intensified that debate.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a fresh 52-week high ahead of the expected Q3 report is driving attention, with traders watching BRIUMVIs sales ramp and guidance. Bullish call flow and heavy short interest have fueled squeeze talk and buyout speculation, though those theories remain unconfirmed and some traders warn the rally may be pricing in strong results.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs record October deliveries and rapid overseas growth are drawing attention, but traders are weighing the sales momentum against the pace needed to meet Q4 goals and concerns about margins amid intense China EV competition. The strong operating updates have not eased frustration over the share-price slide or doubts about profitability.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,811.032761 with 281,866,747.320393 in circulation. The last known price of OFFICIAL TRUMP is 1.57555883 USD and is down -1.93 over the last 24 hours. It is currently trading on 744 active market(s) with $126,884,732.61 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

TRUMP is drawing attention as traders debate a brief speculative bounce in a meme coin widely criticized for its steep decline and losses among holders. Bears call it a pump-and-dump or expect further downside, while a smaller bullish group anticipates another squeeze or rally.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

Discussion centers on the Bitwise funds exposure to XRP, with traders pointing to reported ETF inflows and hopes for regulatory clarity as reasons for optimism. Others are concerned about the funds sharp decline alongside XRP and the broader crypto market, and some remain confused about the difference between the ETF and the XRP token.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Adagene (ADAG) Upgraded to Buy: Here's What You Should Know

Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Are Medical Stocks Lagging  Adagene (ADAG) This Year?

Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Large Increase in Short Interest

Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) saw a significant increase in short interest in April. As of April 15th, there was short interest totaling 411,325 shares, an increase of 477.3% from the March 31st total of 71,244 shares. Approximately 1.1% of the company's shares are...

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Average Recommendation of "Buy" by Analysts

Shares of Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) have been given an average recommendation of "Buy" by the five brokerages that are currently covering the stock, MarketBeat...

Analysts Offer Predictions for Adagene FY2026 Earnings

Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Free Report) - Equities research analysts at HC Wainwright issued their FY2026 earnings estimates for Adagene in a research report issued on Tuesday, April 7th. HC Wainwright analyst A. He forecasts that the company will post earnings of ($0.37) per share fo...

Guggenheim Issues Positive Forecast for Adagene (NASDAQ:ADAG) Stock Price

Guggenheim raised their price target on Adagene from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Monday...

Why Is ADAG Stock Tanking Today?

Equity

Adagene priced the public offering of its American depository shares at $3.75 per ADS, representing a discount of nearly 19% from ADAG’s closing price on Wednesday.

Adagene (NASDAQ:ADAG) Announces Earnings Results, Beats Expectations By $0.24 EPS

Adagene (NASDAQ:ADAG - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28...

Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Expands By 44.6%

Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 13th, there was short interest totaling 74,016...

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Consensus Recommendation of "Buy" by Analysts

Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) has been assigned a consensus rating of "Buy" from the five analysts that are currently covering the company, Marketbeat reports. One...

Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.

Adagene Inc - ADR

Bullish Sentiment

<ul class="summary-bullets"><li>Adagene also announced an update from the Phase 1b/2 study of Muzastotug in combination with Keytruda in patients with Microsatellite Stable Colorectal Cancer with no liver metastases.</li><li>The company stated that the results show an improved durability of response among patients in the trials.</li><li>Adagene added that Muzastotug, in combination with Merck’s Keytruda, has received Fast Track designation from the FDA.</li></ul>Adagene Inc. (ADAG) shares tanked nearly 10% in Thursday’s opening trade after the company announced a slew of updates, including the pricing of a $70 million public offering of its American depository shares.Adagene priced the public offering at $3.75 per ADS, representing a discount of nearly 19% from ADAG’s closing price on Wednesday. The offering is expected to close on April 6, 2026.Adagene also announced an update from the Phase 1b/2 study of Muzastotug in Combination with Keytruda in patients with Microsatellite Stable Colorectal Cancer (MSS CRC) with no liver metastases. The company stated that the results show an improved durability of response among patients in the trials.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ADAG">Adagene</a> trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Adagene Provides Update On Muzastotug Trials</h2>The company stated that Muzastotug, in combination with Merck’s Keytruda, achieved an overall response rate (ORR) of 31% in the combined 20 mg/kg dose cohort, compared to an ORR of 13% in the 10 mg/kg dose cohort.Adagene added that the median duration of response (mDOR) has not yet been achieved in the 20 mg/kg dose cohort, with responses ongoing beyond 9 months. However, the 10 mg/kg dose cohort achieved an mDOR of 6.2 months.The Progression-Free Survival (PFS) stood at 6.7 months in the 20 mg/kg cohort, outlasting the 4.8 months observed in the 10 mg/kg dose cohort, according to the company.Adagene stated that Muzastotug, in combination with Merck’s Keytruda, has received Fast Track designation from the U.S. Food and Drug Administration (FDA).In the 10 mg/kg cohort, the median overall survival was 19.8 months, with 48% of patients alive at two years. In the 20 mg/kg cohort, one-year survival was 80.8%, compared with 70.1% in the 10 mg/kg cohort.The company added that there was a 4% discontinuation rate across the two doses, and that there were no dose-limiting toxicities observed.<h2 class="st-heading-2">Adagene Teams Up With Incyte</h2>Adagene stated that it has partnered with Incyte Corp. (INCY) to evaluate the combination of muzastotug and INCA33890 in patients with MSS CRC with or without liver metastases.The company added that as a monotherapy, INCA33890 has demonstrated promising clinical efficacy and safety in immune checkpoint sensitive and insensitive cancers, including MSS CRC with and without liver metastases.<a href="https://stocktwits.com/symbol/ADAG">ADAG stock</a> is up 130% year-to-date. The Invesco Golden Dragon China ETF (PGJ) is down 14% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-china-made-ev-sales-march-2026/cZ7xoOYRI8R">Tesla’s China-Made EV Sales Rise 9% In March, Registering Fifth Straight Month Of Gains: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Invesco Golden Dragon China ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.51
Prev Close	$2.68
Open	$2.67
Dividend Yield	0.00%
50-Day Moving Average	$3.05
Beta	0.28
Avg. Volume	254,066.98
PE Ratio	-6.65

52-Week High	$4.85
52-Week Low	$1.30
Market Capitalization	$168.53M
EPS (Annual)	-$0.374
Price to Book	1.88
Revenue Per Employee	$60,087.42

Feed

News

Sentiment

Fundamentals

Info

ADAG Fundamentals